Information Provided By: 
Fly News Breaks for June 8, 2017
ANTM, ESRX
Jun 8, 2017 | 08:03 EDT
Cowen analyst Charles Ryhee said concern of margin compression at Express Scripts is unfounded as the company not only receives profits from claims but also prescription drug plan premiums, its rebate administration business, and other business operations. He believes the Express Scripts business mix is the reason for a higher EBITDA per adjusted claim. Ryhee maintained his Outperform rating and $83 price target on Express Scripts shares.
News For ESRX;ANTM From the Last 2 Days
There are no results for your query ESRX;ANTM
